AGP Picks
View all

The LATAM Ledger: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The LATAM Ledger.

Press releases published on July 29, 2026

Onco360® Has Been Selected as a National Pharmacy Partner for VEPPANU™ (vepdegestrant)
Medical Device Injection Molding With Clean Room Assembly Capabilities  | ISO 13485  | THY Precision
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026
Catalyst Acquisition Corp. Announces Closing of $200 Million Initial Public Offering
Alamar Biosciences 推出 NULISAseq™ Immune 340 Panel,实现免疫蛋白质组全面分析
Alamar Biosciences 推出 NULISAseq™ Immune 340 Panel 檢測組合,為免疫蛋白質體作全面分析
Corporation de Minéraux Stratégiques du Maroc annonce une teneur pouvant atteindre 14,88 % de cuivre et de 696 g/t d’argent à Ouneine, ainsi qu’une teneur pouvant atteindre 4,16 g/t d’or à Aït Zekri
Southward Advisors Helps U.S. Manufacturer Achieve $3 Million in Annual Savings Through Mexico Nearshoring Strategy
Aventura en los Extremos: JETOUR G700 y Ed Stafford conquistan los terrenos más duros del mundo
Bitget Ranks Second in ETH Liquidity Depth in H1 2026, CoinGlass Report Finds
Updated Mineral Resource Estimate and publication of Competent Persons Report
BingX Strengthens Market Confidence with Dedicated Trust Center
G3 Goldfields Completes Spin-Out
AbraSilver Announces Closing of C$50 Million “Bought Deal” Public Offering of Common Shares
Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France
NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative
Clene to Present at The Canaccord 46th Annual Growth Conference
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The LATAM Ledger

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.